Nemaura Medical Inc. (NASDAQ: NMRD) Announce Beta Launch of Proprietary ‘MiBoKo’ Metabolic Health Program

October 18, 2021 12:51:16
  • Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
  • The company recently announced the beta launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores
  • US diabetes-related healthcare expenditures totalled $760 billion in 2019 alone, equating to an annual spend of over $9,000 per diabetic patient
Nemaura Medical (NASDAQ: NMRD) is a cutting-edge medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company recently carried out the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI based mobile application ( MiBoKo, an addition to Nemaura Medical’s diabetes-focused product portfolio, has been in development for the past 18 months and seeks to address a significant and growing mass-market opportunity which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores based on glucose tolerance or insulin resistance. Prediabetic patients or those facing obesity concerns or looking to monitor their glucose intake would benefit from using the application. Nemaura Medical’s cutting-edge health tracking program uses a wearable sensor and mobile app that provides users with personalized information by tracking their metabolism when used in conjunction with one another. For example, users can draw insights into how their bodies process sugar by tracking their metabolic health score. This figure provides a holistic overview of the impact of an individual’s daily nutrition on their health. Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer, commented in regard to MiBoKo’s launch, “A person’s response to sugar intake can influence a number of factors from appetite and body weight to sleep patterns, energy levels, and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease, and dementia.” Chowdhury continued, “With MiBoKo, we are able to extend our proprietary non-invasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health.” In addition to receiving real-time updates on their metabolic health scores, MiBoKo users will be eligible to receive weekly and monthly reports illustrating the changes in their metabolic health scores as well as providing a breakdown of how individual habits were impacting their overall health and wellbeing. The MiBoKo application will also suggest how to amend daily routines (i.e., eating more or less of a particular food or exercising during peak energy levels), providing MiBoKo users with granular and actionable intelligence on how to transform their health for the better. Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. Through their flagship product, the sugarBEAT(R), a wearable and non-invasive continuous glucose monitor, and now, the MiBoKo application, Nemaura Medical have sought to improve the health prospects for an ever-increasing proportion of the global population, with US diabetes-related health care expenditures totalling over $760 billion in 2019 alone ( For more information, visit the company’s websites at or NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire (BMW) San Francisco, California 415.949.5050 Office BioMedWire is part of the InvestorBrandNetwork.